Perspective Therapeutics (NYSE:CATX) Coverage Initiated by Analysts at Bank of America

Bank of America initiated coverage on shares of Perspective Therapeutics (NYSE:CATX) in a report issued on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $24.00 price target on the stock.

Several other brokerages also recently issued reports on CATX. Oppenheimer reissued an outperform rating on shares of Perspective Therapeutics in a research note on Tuesday, June 18th. Lifesci Capital reaffirmed an outperform rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. B. Riley raised their price target on shares of Perspective Therapeutics from $12.00 to $17.00 and gave the company a buy rating in a report on Tuesday, April 9th. Cantor Fitzgerald reaffirmed an overweight rating on shares of Perspective Therapeutics in a report on Tuesday, June 25th. Finally, Royal Bank of Canada reaffirmed an outperform rating and set a $30.00 price target on shares of Perspective Therapeutics in a report on Friday, June 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of Buy and a consensus price target of $20.00.

Perspective Therapeutics Stock Up 6.4 %

Shares of NYSE CATX opened at $13.64 on Thursday. Perspective Therapeutics has a 12-month low of $2.05 and a 12-month high of $19.05. The company has a current ratio of 12.98, a quick ratio of 12.98 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $12.46.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. The business had revenue of $0.33 million during the quarter. As a group, equities analysts predict that Perspective Therapeutics will post -1 EPS for the current fiscal year.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, Director Robert F. Williamson III purchased 3,003 shares of Perspective Therapeutics stock in a transaction dated Wednesday, May 29th. The shares were bought at an average cost of $13.30 per share, for a total transaction of $39,939.90. Following the transaction, the director now owns 36,879 shares in the company, valued at approximately $490,490.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Perspective Therapeutics news, Director Robert F. Williamson III purchased 3,003 shares of Perspective Therapeutics stock in a transaction dated Wednesday, May 29th. The shares were bought at an average cost of $13.30 per share, for a total transaction of $39,939.90. Following the transaction, the director now owns 36,879 shares in the company, valued at approximately $490,490.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lori A. Woods purchased 3,424 shares of Perspective Therapeutics stock in a transaction dated Monday, June 3rd. The stock was acquired at an average price of $14.60 per share, for a total transaction of $49,990.40. Following the completion of the transaction, the director now owns 155,398 shares in the company, valued at approximately $2,268,810.80. The disclosure for this purchase can be found here. Insiders have purchased 30,814 shares of company stock worth $385,487 in the last ninety days. 3.52% of the stock is owned by insiders.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently bought and sold shares of CATX. ZWJ Investment Counsel Inc. bought a new stake in Perspective Therapeutics in the 1st quarter valued at about $26,000. Simplicity Wealth LLC acquired a new position in Perspective Therapeutics during the 1st quarter valued at about $40,000. Bleakley Financial Group LLC acquired a new position in Perspective Therapeutics during the 1st quarter valued at about $40,000. RIA Advisory Group LLC increased its stake in Perspective Therapeutics by 1,313.4% during the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after buying an additional 99,293 shares during the period. Finally, Virtu Financial LLC acquired a new position in Perspective Therapeutics during the 1st quarter valued at about $138,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.